Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.

Kolstad A, Pedersen LB, Eskelund CW, Husby S, Grønbæk K, Jerkeman M, Laurell A, Räty R, Elonen E, Andersen NS, Brown PD, Kimby E, Bentzen H, Sundström C, Ehinger M, Karjalainen-Lindsberg ML, Delabie J, Ralfkiær E, Fagerli UM, Nilsson-Ehle H, Lauritzsen GF, Kuittinen O, Niemann C, Geisler CH; Nordic Lymphoma Group.

Biol Blood Marrow Transplant. 2017 Mar;23(3):428-435. doi: 10.1016/j.bbmt.2016.12.634. Epub 2016 Dec 27.

2.

15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.

Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, Smedby KE, Husby S, Pedersen LB, Andersen NS, Eriksson M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Workman CT, Garde C, Elonen E, Brown P, Grønbaek K, Geisler CH.

Br J Haematol. 2016 Nov;175(3):410-418. doi: 10.1111/bjh.14241. Epub 2016 Jul 5.

PMID:
27378674
3.

A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma.

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Østenstad B, Kvaløy S, Holte H.

Br J Haematol. 2016 May;173(3):432-43. doi: 10.1111/bjh.13965. Epub 2016 Feb 23.

PMID:
26914167
4.

Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway.

Smeland KB, Kiserud CE, Lauritzsen GF, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Kvaløy S, Holte H.

Haematologica. 2015 Jun;100(6):e240-3. doi: 10.3324/haematol.2014.119214. Epub 2015 Feb 14. No abstract available.

5.

Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.

Kolstad A, Laurell A, Jerkeman M, Grønbæk K, Elonen E, Räty R, Pedersen LB, Loft A, Bogsrud TV, Kimby E, Hansen PB, Fagerli UM, Nilsson-Ehle H, Lauritzsen GF, Lehmann AK, Sundstrom C, Karjalainen-Lindsberg ML, Ralfkiaer E, Ehinger M, Delabie J, Bentzen H, Schildt J, Kostova-Aherdan K, Frederiksen H, Brown Pde N, Geisler CH; Nordic Lymphoma Group.

Blood. 2014 May 8;123(19):2953-9. doi: 10.1182/blood-2013-12-541953. Epub 2014 Mar 20.

6.

High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era.

Blaker YN, Eide MB, Liestøl K, Lauritzsen GF, Kolstad A, Fosså A, Smeland EB, Holte H.

Leuk Lymphoma. 2014 Oct;55(10):2319-27. doi: 10.3109/10428194.2013.871632. Epub 2014 Mar 19.

PMID:
24432894
7.

Multimodal treatment with ALL-like chemotherapy, Auto-SCT and radiotherapy for lymphoblastic lymphoma.

Bersvendsen H, Kolstad A, Blystad AK, Aurlien E, Fosså A, Kvaløy SO, Holte H, Lauritzsen GF.

Acta Oncol. 2014 May;53(5):680-7. doi: 10.3109/0284186X.2013.855816. Epub 2013 Nov 18.

PMID:
24237392
8.

High-dose therapy with autologous stem cell support for lymphoma--from experimental to standard treatment.

Smeland KB, Kiserud CE, Lauritzsen GF, Fosså A, Hammerstrøm J, Jetne V, Kolstad A, Kvalheim G, Loge JH, Løkeland T, Tangen JM, Holte H, Kvaløy S.

Tidsskr Nor Laegeforen. 2013 Sep 3;133(16):1735-9. doi: 10.4045/tidsskr.13.0319. English, Norwegian.

9.

High-dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008.

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Fluge Ø, Fosså A, Hammerstrøm J, Kolstad A, Loge JH, Maisenhølder M, Østenstad B, Kvaløy S, Holte H.

Tidsskr Nor Laegeforen. 2013 Sep 3;133(16):1704-9. doi: 10.4045/tidsskr.13.0243. English, Norwegian.

10.

Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.

d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, Holte H, Österborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Østenstad B, Fagerli UM, Gadeberg OV, Sundström C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod HE.

J Clin Oncol. 2012 Sep 1;30(25):3093-9. doi: 10.1200/JCO.2011.40.2719. Epub 2012 Jul 30.

PMID:
22851556
11.

Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.

Geisler CH, Kolstad A, Laurell A, Jerkeman M, Räty R, Andersen NS, Pedersen LB, Eriksson M, Nordström M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E; Nordic Lymphoma Group.

Br J Haematol. 2012 Aug;158(3):355-62. doi: 10.1111/j.1365-2141.2012.09174.x. Epub 2012 May 29. Erratum in: Br J Haematol. 2012 Sep;158(6):815-6.

PMID:
22640180
12.

Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation.

Fløisand Y, Brinch L, Gedde-Dahl T, Tjønnfjord GE, Dybedal I, Holte H, Heldal D, Torfoss D, Aurlien E, Lauritzsen GF, Fosså A, Lehne G, Baggerød E, Kvalheim G, Egeland T, Bishop MR, Fowler DH, Kolstad A.

Bone Marrow Transplant. 2012 Dec;47(12):1552-7. doi: 10.1038/bmt.2012.63. Epub 2012 Apr 23.

PMID:
22522568
13.

Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis.

Fosså A, Fiskvik IH, Kolstad A, Lauritzsen GF, Aurlien E, Blystad AK, Hole KH, Ikonomou IM, Holte H.

Ann Oncol. 2012 May;23(5):1254-9. doi: 10.1093/annonc/mdr385. Epub 2011 Sep 16.

PMID:
21926399
14.

High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study.

Eide MB, Lauritzsen GF, Kvalheim G, Kolstad A, Fagerli UM, Maisenhölder M, Østenstad B, Fluge Ø, Delabie J, Aarset H, Liestøl K, Holte H.

Br J Haematol. 2011 Mar;152(5):600-10. doi: 10.1111/j.1365-2141.2010.08519.x. Epub 2011 Jan 17. Review.

PMID:
21241276
15.
16.

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).

Geisler CH, Kolstad A, Laurell A, Räty R, Jerkeman M, Eriksson M, Nordström M, Kimby E, Boesen AM, Nilsson-Ehle H, Kuittinen O, Lauritzsen GF, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E; Nordic Lymphoma Group.

Blood. 2010 Feb 25;115(8):1530-3. doi: 10.1182/blood-2009-08-236570. Epub 2009 Dec 23.

17.

Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.

Andersen NS, Pedersen LB, Laurell A, Elonen E, Kolstad A, Boesen AM, Pedersen LM, Lauritzsen GF, Ekanger R, Nilsson-Ehle H, Nordström M, Fredén S, Jerkeman M, Eriksson M, Väärt J, Malmer B, Geisler CH.

J Clin Oncol. 2009 Sep 10;27(26):4365-70. doi: 10.1200/JCO.2008.21.3116. Epub 2009 Aug 3.

PMID:
19652064
18.

Mantle cell lymphoma with partial involvement of the mantle zone: an early infiltration pattern of mantle cell lymphoma?

Bassarova A, Tierens A, Lauritzsen GF, Fosså A, Delabie J.

Virchows Arch. 2008 Oct;453(4):407-11. doi: 10.1007/s00428-008-0621-x. Epub 2008 Aug 12.

PMID:
18696109
19.

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.

Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, Eriksson M, Nordström M, Kimby E, Boesen AM, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Akerman M, Ehinger M, Sundström C, Langholm R, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E; Nordic Lymphoma Group.

Blood. 2008 Oct 1;112(7):2687-93. doi: 10.1182/blood-2008-03-147025. Epub 2008 Jul 14.

20.

Clinical effect of buffy-coat vs. apheresis platelet concentrates in patients with severe thrombocytopenia after intensive chemotherapy.

Akkök CA, Brinch L, Lauritzsen GF, Solheim BG, Kjeldsen-Kragh J.

Vox Sang. 2007 Jul;93(1):42-8.

PMID:
17547564
21.

Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma.

Kolstad A, Nome O, Delabie J, Lauritzsen GF, Fossa A, Holte H.

Leuk Lymphoma. 2007 Mar;48(3):570-6.

PMID:
17454601
22.

Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: a prospective, randomized, multicentre trial.

Torfoss D, Høiby EA, Tangen JM, Holte H, Bø K, Meyer P, Grøttum K, Weyde K, Lauritzsen GF, Sandstad B, Jacobsen AB, Olsen H, Kvaløy S.

J Antimicrob Chemother. 2007 Apr;59(4):711-7. Epub 2007 Feb 27.

PMID:
17327294
23.

Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen.

Kolstad A, Holte H, Fosså A, Lauritzsen GF, Gaustad P, Torfoss D.

Haematologica. 2007 Jan;92(1):139-40.

24.

Peripheral T-cell lymphoma with involvement of the expanded mantle zone.

Ikonomou IM, Tierens A, Troen G, Aamot HV, Heim S, Lauritzsen GF, Vålerhaugen H, Delabie J.

Virchows Arch. 2006 Jul;449(1):78-87. Epub 2006 Apr 22.

PMID:
16633785
25.

Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens.

Smeland S, Blystad AK, Kvaløy SO, Ikonomou IM, Delabie J, Kvalheim G, Hammerstrøm J, Lauritzsen GF, Holte H.

Ann Oncol. 2004 Jul;15(7):1072-8.

PMID:
15205201
26.

Clonal deletion of thymocytes as a tumor escape mechanism.

Lauritzsen GF, Hofgaard PO, Schenck K, Bogen B.

Int J Cancer. 1998 Oct 5;78(2):216-22.

27.

Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies.

Bogen B, Munthe L, Sollien A, Hofgaard P, Omholt H, Dagnaes F, Dembic Z, Lauritzsen GF.

Eur J Immunol. 1995 Nov;25(11):3079-86.

PMID:
7489746
28.

Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors.

Lauritzsen GF, Weiss S, Dembic Z, Bogen B.

Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5700-4.

30.

Anti-tumour activity of idiotype-specific, MHC-restricted Th1 and Th2 clones in vitro and in vivo.

Lauritzsen GF, Weiss S, Bogen B.

Scand J Immunol. 1993 Jan;37(1):77-85.

PMID:
8418475
31.

Supplemental Content

Loading ...
Support Center